Next Generation Complement Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Next Generation Complement Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Next Generation Complement Therapeutics Market By Molecule Type (Biologics And Small Molecules), By Route Of Administration (Intravenous, Oral, And Subcutaneous), By Therapy Type (Monotherapy And Combination Therapy), By Application (Cardiovascular, Genetic, Hematological, Infectious, Neurological And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the rising prevalence of cardiovascular, genetic, infectious and other diseases, the growing geriatric population, and the increasing advancements in the next generation complement therapeutics product arena across the globe.

The global Next Generation Complement Therapeutics Market is estimated to grow at a CAGR of 15.39% during the forecast period from 2024 to 2030. The Next Generation Complement Therapeutics market is observing an optimistic market growth due to an increase in the prevalence of cardiovascular, genetic, infectious, and neurological disorders globally, further, the growing geriatric population and the rising advancements in the Next Generation Complement Therapeutics products across the globe is also expected to result in appreciable revenue growth in the Next Generation Complement Therapeutics market during the forecast period (2024-2030).

Next Generation Complement Therapeutics Market Dynamics:

One of the main factors for the growth of the Next Generation Complement Therapeutics market is the increasing geriatric population people globally. As per the World Health Organization (WHO) data published in October 2022, it was estimated that between the years 2015-2050 the number of individuals aged 60 years and more will be doubled from 12-22% and will reach 2.1 billion by 2050. Additionally, by the year 2030, one out of every six individuals in the world will be aged 60 years or beyond.

Also, according to the abovementioned source, the number of individuals aged 80 years or more is expected to get tripled between the years 2020 and 2050 to reach 426 million population. As age increases chances of suffering from infectious, neurological, respiratory, and cardiovascular diseases such as asthma, COPD, heart attacks, coronary artery disease, Alzheimer’s disease, and others also increase. The geriatric population is at the maximum risk of getting infected by diseases due to various factors such as decreased lung capacity, weaker immune system, reduced bone & muscle mass, and lowered ability for physical activity, due to which the heart pumps less blood and delivering less oxygen to the body.

Thus, due to such bodily changes with age, the significant increase in the old age population can be directly linked to an increase in the population suffering from various diseases. Therefore, the rising geriatric population requiring more therapeutics would spur the market demand for next-generation complement therapeutics during the forecast period (2024-2030)

Along with this, the rising product developmental activities in the next generation therapeutics market is also expected to drive its market growth during the forecast period. In January 2022, Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development for licensing next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

However, certain factors such as stringent regulatory approvals and guidelines for the next- generation complement therapeutics market, the undiagnosed population living with complement deficiencies, and others may act as restraints for the Next Generation Complement Therapeutics market growth.

The Next Generation Complement Therapeutics market was positively impacted during the COVID-19 pandemic owing to the rising research and development activities, leading to product launches among the general public. The COVID-19 pandemic also led to a rising number of COVID-19 patients and increasing biologics and drug launches for the treatment of COVID-19. Moreover, the vaccine development of COVID-19 has initiated the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of activities across the pharmaceutical and healthcare sector, thereby bringing the demand for products on track in the next generation complement therapeutics market.

Next Generation Complement Therapeutics Market Segment Analysis:

Next Generation Complement Therapeutics Market by molecule type (biologics and small molecules), route of administration (intravenous, oral, and subcutaneous), therapy type (monotherapy and combination therapy), application (cardiovascular, genetic, hematological, infectious, neurological, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the molecule type of the Next Generation Complement Therapeutics market, the biologics segment is expected to have a significant revenue share in the year 2023. This is primarily due to the rising prevalence of COVID-19 infections and other autoimmunediseases around the world and the rising product developmental activities in the biologics sector, thus driving the overall Next Generation Complement Therapeutics market.

The COVID-19 pandemic was one of the most severe pandemics that the world faced, stressing the importance of developing advanced and next-generation pharmaceuticals, to immunize and tackle the global pandemic.

According to the WHO data (2023), as of 29 November 2022, a total of 13,042,112,489 vaccine doses had been administered to the population worldwide, which have been made possible through next-generation biologics. Moreover, biologics are also used for protection against various diseases in adolescents will further spur its market growth.

In addition, as per the National Stem Cell Foundation (2023), nearly 4% of the global population gets affected by more than 80 different types of autoimmune diseases on an average such as rheumatoid arthritis, myasthenia gravis, Crohn’s disease, psoriasis, scleroderma among others.

Owing to the large patient pool requiring immunity from COVID-19 and other autoimmune diseases various vaccines have recently beenapproved as next-generation complement therapeutics in the biologics sector for their treatment, thus further expanding their market growth. For example, In November 2022, Sanofi and GSK’s next-generation COVID-19 booster vaccine VIDPREVTYN® BETA got approved by the European Commission, which is the first and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe.

In a similar instance, in November 2022, argenx SE, a global immunology company announced the U.S. Food and Drug Administration (FDA) acceptance granting a Biologics License Application (BLA) for SC efgartigimod (1000mg efgartigimod-PH20) for the treatment of adult patients with generalized myasthenia gravis (gMG).

Therefore, due to such rising demand for biologics coupled with the recent regulatory approvals, the market for biologics in the Next Generation Complement therapeutics market is expected to grow significantly during the forecast period.

North America is expected to dominate the overall Next-Generation Complement Therapeutics Market:

Among all the regions, North America is expected to dominate the global Next Generation Complement Therapeutics market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the rising prevalence of cardiovascular and neurological diseases, among others, and the rising research and development activities in North America during the forecast period from 2024-2030.

According to the latest study conducted by the Centre for Disease Control and Prevention (CDC), about 697,000 people in the United States died from heart disease in 2020, and about 20.1 million adults aged 20 and older had coronary artery disease (CAD). Moreover, the US was the most affected country in the world by the COVID-19 pandemic, recording the highest number of cases and deaths during the pandemic phase.

Moreover, according to the Pan American Health Organization (2023), the age-standardized death rate from the neurological condition was highest in the US, being 47.4 deaths per 100,000 population) in 2019. The mortality rate can be controlled by treating or managing the disease by giving proper therapeutic options to people, ultimately increasing the demand for Next Generation Complement Therapeutics in the North American region.

In May 2022, the US-based biotechnology company Dianthus Tx, announced the completion of its $100 million Series A financing led by 5AM Ventures and various other partners to expand leadership and scientific teams, advance the company's lead program, DNTH103, to accelerate additional discovery pipeline programs for people living with severe and rare autoimmune diseases. DNTH103 is a potent, next-generation monoclonal antibody that selectively targets the active form of complement C1s, potentially enabling a lower dosing volume and a less frequent subcutaneous administration that is further enhanced with half-life extension technology.

Therefore, the interplay of the above-mentioned factors would provide a conducive growth environment for the North America Next Generation Complement Therapeutics market during the forecast period.

Next Generation Complement Therapeutics Market Key Players:

Some of the key market players operating in the Next Generation Complement Therapeutics Market include Roche, Amgen, CSL Bearings, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, UCB, and others.

Recent Developmental Activities in the Next-Generation Complement Therapeutics Market:

In November 2022, Sanofi and GSK’s next-generation COVID-19 booster vaccine VIDPREVTYN® BETA got approved by the European Commission, which is the first and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe.

In May 2022, the US-based biotechnology company Dianthus Tx, announced the completion of its $100 million Series A financing led by 5AM Ventures and various other partners to expand leadership and scientific teams, advance the company's lead program, DNTH103, to accelerate additional discovery pipeline programs for people living with severe and rare autoimmune diseases.

In February 2022, US FDA approved Enjaymo™ (sutimlimab-jome) for use in patients with cold agglutinin disease and is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD).

Key Takeaways from the Next Generation Complement Therapeutics Market Report Study

Market size analysis for current Next Generation Complement Therapeutics Market size (2023), and market forecast for 6 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Next Generation Complement Therapeutics market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global Next Generation Complement Therapeutics market.

Various opportunities available for the other competitor in the Next Generation Complement Therapeutics Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current Next Generation Complement Therapeutics Market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Next Generation Complement Therapeutics Market growth in the coming future?

Target Audience who can be benefited from this Next Generation Complement Therapeutics Market Report Study

Next Generation Complement Therapeutics products providers

Research and development organizations

Next Generation Complement Therapeutics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Next Generation Complement Therapeutics

Various end users who want to know more about the Next Generation Complement Therapeutics Market and the latest innovations in the Next Generation Complement Therapeutics market.

Frequently Asked Questions for Next Generation Complement Therapeutics Market:

1. What is Next Generation Complement Therapeutics?

Next Generation Complement Therapeutics help in the inhibition of the outgrowth of pathogens thereby inhibiting complement activation, thus reducing tissue inflammation, and dampening the adaptive immune response to foreign and tissue antigens.

2. What is the global market for Next Generation Complement Therapeutics?

The global Next Generation Complement Therapeutics Market is estimated to grow at a CAGR of 15.39% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Next Generation Complement Therapeutics market?

The Next Generation Complement Therapeutics market is witnessing positive growth due to an increase in the prevalence of cardiovascular, genetic, infectious, neurological, and others globally, the growing geriatric population, and the rising advancements in the Next Generation Complement Therapeutics products around the world, which is further expected to result in appreciable revenue growth of the Next Generation Complement Therapeutics market during the forecast period (2024-2030).

4. Who are the key players operating in the global Next Generation Complement Therapeutics market?

Some of the key market players operating in the Next Generation Complement Therapeutics Market include Roche, Amgen, CSL Bearings, Innovent Biologics, Novartis, Regeneron, Sanofi, Takeda, UCB, and others.

5. Which region has the highest share in the Next Generation Complement Therapeutics market?

Among all the regions, North America is estimated to amass a significant revenue share in the global Next Generation Complement Therapeutics market. This can be ascribed to the rising prevalence of cardiovascular, and neurological diseases, the COVID-19 pandemic, and the rising research and development activities in North America during the forecast period from 2024-2030.